[Skip to Content]
[Skip to Content Landing]
December 1997

Narrowband UV-B and Psoriasis

Author Affiliations

Department of Dermatology Beth Israel Deaconess Medical Center 330 Brookline Ave, LY-134 Boston, MA 02215

Arch Dermatol. 1997;133(12):1587-1588. doi:10.1001/archderm.1997.03890480109019

IN THE United States, UV-B phototherapy is probably the most frequently used treatment for moderate to severe psoriasis. In the 1970s and early 1980s, a number of important studies increased our understanding of how best to use UV-B light to treat psoriasis.1-5 Despite the increased use of this treatment, in the last decade few clinical studies have quantified the relative efficacy and safety of different treatment protocols (eg, suberythemogenic vs erythemogenic) and alternative UV-B light sources for the treatment of psoriasis.

One of the most important insights of the 1980s was contributed by Parrish and Jaenicke,6 who demonstrated that wavelengths near 313 nm were most efficient for clearing psoriasis.Nearly a decade has elapsed since European dermatologists put this experimental observation into practice.7,8 By using newly engineered, high-output, narrowband UV-B lamps (TL-01, Philips Lighting Co, Sommerset, NJ), with peak output near 311 nm, they demonstrated that narrowband UV-B

First Page Preview View Large
First page PDF preview
First page PDF preview